Olympia Launches Gonadorelin Injection in 503B Portfolio

Compounded gonadorelin is now shipping from a 503B outsourcing facility, raising the bar for formulation consistency in men's hormone protocols. Olympia Pharmaceuticals, an FDA-registered 503B and 503A operation based in Orlando, has added a Gonadorelin 1 mg/mL injection to its catalog, available across 49 states for both office-use and patient-specific prescriptions.

The formulation is supplied in a 5 mL vial configured for intravenous, intramuscular, or subcutaneous administration. It requires no reconstitution, ships refrigerated, and is protected from light, specifications that reduce preparation variables at the point of care. For QA directors evaluating outsourced compounded injectables, the ready-to-use format shifts sterility assurance responsibility squarely to the compounding facility rather than the clinical site.

Gonadorelin is a synthetic gonadotropin-releasing hormone (GnRH) analogue. Administered as part of individualized hormone optimization protocols, it stimulates luteinizing hormone and follicle-stimulating hormone release, which in turn signals endogenous testosterone production. Its clinical utility sits alongside, and sometimes in place of, exogenous testosterone replacement, making formulation reliability a direct patient-safety consideration.

For regulatory affairs leads, the 503B designation is the operative detail. Under 21 CFR Part 503B, outsourcing facilities must comply with current good manufacturing practice requirements, including full batch records, environmental monitoring, and container-closure integrity testing. That framework distinguishes 503B-compounded product from traditional 503A pharmacy dispensing and positions it closer to conventional drug manufacturing in terms of oversight expectations. Olympia's expansion of its hormone catalog under this registration signals continued investment in GMP-compliant infrastructure to support high-volume clinical accounts.

The commercial context is relevant to plant heads and procurement leads at competing facilities. Men's health has become a primary revenue driver for many specialty practices, and the demand for compounded hormone formulations, testosterone, human chorionic gonadotropin, and now gonadorelin, has grown accordingly. Facilities that can offer a consolidated, GMP-compliant hormone portfolio under one 503B registration carry a structural advantage in account retention.

Olympia's gonadorelin launch will be measured, in part, by how consistently the formulation performs across the clinical accounts now ordering it in 49 states.

Source: GlobeNewswire via Olympia Pharmaceuticals press release, September 1, 2026.